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Summary. Laboratory evaluation of bleeding disorders
has been performed with the standard clotting assays
such as the PT and PTT for several decades. Our
improved understanding of the process of blood
coagulation has now revealed the important role played
by the cellular elements such as platelets, monocytes
and red blood cells. The need for a test that can assess
clotting in a more ‘global’ manner, beyond the initiation
of clot formation, has led to greater interest in assays
such as thrombin generation and thromboelastography.
Even though there are several publications using
thromboelastography it remains a research tool as the
methodology is not standardized. In an attempt to show
reproducibility and consistency using thromboelasto-
graphy, a group of investigators from different coun-
tries joined hands to form the TEG-ROTEM Working
Group. Two studies were performed using PRP and
FVIII deficient plasma and an intrinsic pathway
activator. This article summarizes the results of the
first international effort at standardization of throm-
boelastography. Both of the instruments using this
technology (TEG and ROTEM) were used. Nine
laboratories from countries around the globe partici-
pated in this effort. The results showed a significant
inter-laboratory variance with CV’s greater than 10%.
Although these results were not satisfactory, this
has been the first effort to standardize this methodology
and significant work remains to be done to improve
reliability and reproducibility. These studies were
performed on PRP and the results may be more reliable
when preformed on whole blood samples. We believe
that it is important to continue this work so that we
may investigate the usefulness and potential appli-
cations of thromboelastography in the evaluation of
bleeding and thrombosis.
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Introduction
Thromboelastography is a global assay of haemostatic
function, from the beginning of clot formation to the
end of fibrinolysis. Two systems utilizing this technol-
ogy include Thrombelastograph/TEG (Haemonetics,
Braintree, MA, USA) and ROTEM (Pentapharm
GmbH, Munich, Germany). They are simple to use
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and proven to be effective methods of intraoperative
monitoring to optimize blood product selection and
utilization and have been shown to improve outcomes
during complex surgical procedures such as cardiotho-
racic surgery and liver transplantation [1,2]. Case
reports or small case series have addressed the useful-
ness of thromboelastography in the management of
bleeding or monitoring of treatment with bypassing
agents [3,4]. In order to establish the usefulness of this
test a standardized methodology needs to be developed
and reproducibility and consistency have to be demon-
strated. In an attempt to initiate this process, the TEG-
ROTEM Working group was established in 2006 and
investigators from several countries joined hands to
perform these studies. Herein we present the results of
the first international study, wherein nine laboratories
from six countries (Canada, Denmark, Israel, Norway,
UK and USA) participated.
Materials and methods
The main components of the thromboelastograph con-
sist of a cylindrical cup and a pin. In the TEG the cup
is oscillated through an angle of 445¢ over a 10 s
interval, while in the ROTEM, the pin oscillates and
the cup remains stationary. The torque of the cup is
transmitted to the pin through sample viscosity in the
cup. Unclotted blood transmits little or no torque from
cup to pin. As the blood clots, fibrin fibres form between
the cup and pin, transferring a portion of the cup’s
motion to the pin. With clot lysis the torque decreases.
The computerized system automatically records kinetic
changes in the whole blood sample. The clots physical
properties, such as the rate of clot formation, the
strength and stability of the clot are thereby recorded by
the system, and are dependent on the interaction of the
coagulation factors, platelets and fibrinogen. The trac-
ing produced is called the thromboelastogram as shown
in Fig. 1.
The TEG and ROTEM although similar have
minor differences in the mechanical aspects. This is
represented in Table 1.
Even though the parameters are identical there are
differences in the diagnostic nomenclatures.
1. Coagulation time: R on TEG and CT on
ROTEM.
2. Clot Formation time: K on TEG and CFT on
ROTEM.
3. Maximum Clot Firmness: MA on TEG and MCF
on ROTEM
4. Shear Elastic Modulus Strength: G on both instru-
ments.
5. a/Angle-Rate of polymerization of clot: a on both
instruments.
While there are several other parameters available on
both instruments to measure other parameters of
coagulation and clot lysis, the above represent the
common parameters used to assess coagulation.
Since the TEG and ROTEM are similar yet not
identical, the objective of our efforts was to determine
if the same instrument could produce similar results
when under similar conditions, thereby proving repro-
ducibility and consistency. We did not intend to
compare between the two instruments, TEG and
ROTEM.
In order to assess the reproducibility of the throm-
boelastographic parameters on both the TEG and
ROTEM two sets of experiments were conducted
using the initiator for the intrinsic pathway provided by
the manufacturers of the instruments (Kaolin/Intem)
first with platelet rich plasma (PRP) and in the second
experiment both normal pooled plasma and factor VIII
(FVIII) deficient plasma were evaluated. The object of
this study was to establish consistency and reproduc-
ibility between laboratories using the same method on
the same instrument.
In order to ensure that the instruments were in good
working order it was determined that the date of the last
maintenance check was within 6 months of running the
test.
Since PRP is more stable during storage and trans-
portation, this was determined to be the sample of
choice. A pool of normal as well as FVIII deficient
plasma was provided by Center for Hemophilia and
Fig. 1. The thromboelastography trace.
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Thrombosis, Aarhus University Hospital, Skejby, Den-
mark (Ingerslev & Sorensen). Although whole blood is
the sample of choice for these assays, this was a
limitation that was foreseen.
Method: Intrinsic activation was evaluated using
standard reagents (Same lot number) provided by the
manufacturers: Kaolin from Haemoscope and InTEM
from Pentapharm. Samples were run using the same
protocol as recommended for whole blood by the
manufacturer.
For the TEG: Each aliquot of plasma was thawed
for 10 min in a water bath at 37C. One mL of the
plasma was then transferred to the kaolin vial and
mixed by inverting it five times. Then 340 mL of the
kaolin/plasma mixture was transferred via reverse
pipetting into the TEG cup already containing 20 lL
of the CaCl2 supplied with kit, and recording was
initiated. The temperature was maintained at 37C
during the testing. Since this methodology is very
sensitive to the technique, reverse pipetting was used
for all steps in the testing. All precautions were taken to
minimize the appearance of bubbles in the sample cup
as this has been noted to activate the sample. All tests
were recorded for a minimum of 60 min. The above
procedure was repeated twice with the same TEG
equipment on three different days for a total of 12
recordings/instrument of 60 min each.
For the ROTEM: Each aliquot of plasma was
thawed for 10 min in a water bath at 37C. 300 lL of
plasma was transferred to ROTEM cup already con-
taining 20 lL InTEM and 20 lL starTEM (buffered,
specifically concentrated calcium chloride solution sup-
plied by manufacturer) and recording was initiated.
Temperature was maintained at 37C during the testing.
Electronic pipette was preferred to be used for all runs.
If manual pipetting was used, reverse pipetting was
recommended. All attempts were made to minimize the
appearance of bubbles in the sample cup and all tests
were run for a minimum of 60 min. The above
procedure was repeated twice with the same ROTEM
equipment on three different days for a total of 24
recordings/instrument of 60 min.
Both normal and abnormal plasma were tested in a
similar manner.
Parameters normally used to assess the process of
coagulation were determined to be: Coagulation time
(R on TEG and CT on ROTEM), Clot formation
time (K on TEG and CFT on ROTEM), Maximum
clot firmness (MA on TEG and MCF on ROTEM),
Shear Elastic Modulus Strength or clot strength (G on
both instruments), and a/Angle-Rate of polymerization
of clot: (a on both instruments) and therefore it would
be important to achieve reproducibility in these.
Six assays were conducted for each parameter, for
normal as well as abnormal controls. The six assays are
split into three sessions of two assays.
Our first task included 5 ROTEM’s and 6 TEG’s
from five different laboratories. This study was mainly
Table 1. Characteristics of the TEG and ROTEM.
TEG ROTEM
Two channels Four channels
A pin connected with a torsion wire, is inserted into the sample.
Sample cup oscillates
The pin (sensor) is fixed on the tip of a rotating shaft which is guided by a ball
bearing system. The shaft rotates back and forth. Sample cup is stationary
Mixing of the contents in the sample cup is done with the oscillation of
the cup over the pin.
Mixing of the contents in the cup is accomplished by re-aspirating into the
automated pipette.
Activators used:
KAOLIN: Vial coated with kaolin to which 1 mL
blood per plasma is added. Volume sufficient to run two channels
Activators used:
INTEM: Partial thromboplastin phospholipids made from rabbit brain. Blood is
not mixed outside the cup therefore only 400 lL required per test.
Sample volume: 360 lL Sample volume: 340 lL
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limited by the availability of pooled normal plasma.
Our second effort was better organized and included
nine laboratories from around the globe and 11
ROTEM’s and 6 TEG’s.
Statistical Analysis
Means and SD’s for each run and each laboratory were
calculated and compared using the Student t-test. A
co-efficient of variance (CV) was calculated from the
means and SD for the entire group. Inter laboratory
variance was evaluated using the anova. Each instru-
ment (TEG and ROTEM) was formally and individ-
ually evaluated in this manner.
Results
Since the second task included a larger number of
laboratories and both PRP and FVIII deficient plasma
were used, the results presented below were those
obtained in Task 2.
TEG: The means and SD’s for the 28 runs, 14 from
each channel are shown in Tables 2 and 3. There were
no significant differences between channels.
ROTEM: The means and SD’s from the 120 runs on
5 ROTEM’s are shown in the Tables 4 and 5. Thirty
runs each were performed with both PRP and FVIII
deficient plasma.
Information on reproducibility as conducted by the
American Proficiency Institute and the College of
American Pathologists (CAP) is shown in Table 6.
These institutions provide proficiency certifications to
laboratories to ensure acceptable standards of testing.
These are results for the year 2007 and mostly
performed by perfusionists, since the TEG is licenced
in the US as a point of care instrument to guide
transfusion requirements. Table 6 shows excellent
reproducibility and the number of laboratories partic-
ipating in this exercise is significant. However, they are
using lyophilized plasma and also there is no initiator
and the differences in strength of the initiator do not
exist.
An attempt was made to determine if there was a
correlation between laboratory variation and the high
CV’s seen on our results.
As seen in Fig. 2, variables such as CT and MCF
which are parameters that are more commonly used
have a lower CV, compared to the CFT or a angle.
Similar variations were seen in CV’s between labora-
tories on TEG with FVIII deficient plasma as shown in
Fig. 3. The CV’s were higher for the K value on the
TEG which is the same as the CFT on the ROTEM.
Among the parameters that were measured, it is
important to note that the CV for the R/CT and MA/
MCF were less than 20%. Although these are not
acceptable for a routine laboratory assay, these may be
related to the differences in the activators or the use of
frozen plasma which may be avoided if whole blood is
used for the assay. The other parameters such as K and
a angle have been known to have increased variability
and are also not used often in routine practice for
Table 6. Reproducibility as demonstrated by the CAP.
R K A MA
Mean 1.46 0.80 82.67 52.83
SD 0.26 0.03 1.47 2.95
Range 0.7–2.3 0.8–1.1 75.3–85.9 42.6–64.4
SD, standard deviation.
Table 4. ROTEM parameters with PRP.
CT CFT A MCF G
Mean 152.59 346.93 78.26 34.43 2690.3
SD 21.44 135.53 2.44 4.99 571.93
CV 14.05 39.07 3.12 14.49 21.26
SD, standard deviation; CV, coefficient of variance.
Table 5. ROTEM parameters with FVIII deficient plasma.
CT CFT A MCF G
Mean 487.93 373.64 45.84 37.15 3024.7
SD 64.22 191.51 7.51 5.91 752.08
CV 13.16 51.25 16.39 15.90 24.87
SD, standard deviation; CV, coefficient of variance.
Table 3. TEG Parameters with factor VIII Deficient Plasma.
R K A MA G
Mean 28.58 16.212 24.90 32.25 2.45
SD 2.45 5.04 11.78 7.07 0.83
CV 8.58 31.14 47.29 21.91 33.88
CV, co-efficient of variance.
Table 2. TEG Parameters with PRP.
R K A MA G
Mean 4.38 2.38 74.51 39.45 3.39
SD 0.74 1.43 5.26 7.74 1.1
CV 17 59.98 7.06 19.62 32.55
CV, co-efficient of variance.
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Fig. 2. Variation in CV between laboratories on ROTEM with FVIII
deficient plasma.
STANDARDIZATION OF THROMBOELASTOGRAPHY 535
 2011 Blackwell Publishing Ltd Haemophilia (2011), 17, 532–537
clinical judgment. We hope that by using whole blood
these CV’s may show improvement and probably reach
acceptable levels.
Discussion
Thromboelastography was first developed by Dr. Hell-
mut Hartert at University of Heidelberg School of
Medicine in 1948. It is an elastic modulus based
assessment of hemostasis that is gaining popularity in
research and clinical settings since the availability of the
newly improved analyzers. It is currently used in the
point of care management of acute peri-operative
bleeding. The two currently available instruments using
this principal are the TEG and the ROTEM.
Classical thromboelastography is a global assay of
coagulation which allows the rapid assessment of
coagulation and fibrinolysis using native whole blood,
anticoagulated citrated recalcified whole blood or acti-
vated whole blood. Since it does not provide any
quantitative analysis of clotting or anticoagulant fac-
tors, it remains a research tool in hematology [5]. With
the emergence of interest in global assays in coagulation
which may provide a more physiological approach to
the study of the process of hemostasis, there has been
resurgence in interest in tests such as thromboelastog-
raphy and thrombin generation.
Thromboelastography has now been tested in various
clinical scenario such as, perioperatively in cardiac and
hepatic surgery and transplantation to decrease the
number of transfusions [1,6], as a screening tool for
hypercoaguability [7] and recently for the management
of bleeding in patients with bleeding disorders [3,4,8].
Several recent publications have also attempted to assess
hypercoaguability using thromboelastography [7,9].
This method has also been shown to be useful in
assessing the bleeding tendency in patients with bleed-
ing disorders [10,11]. While it is gaining popularity in
the clinical arena, the methodology remains at the
discretion of the user/manufacturer. There are a few
studies that have attempted to determine the validity
and/or reliability of the two instruments, but they have
been few and far between [5,12,13].
In an attempt to standardize the methodology and to
determine if the tests performed on both instruments
are reliable and reproducible when the standard
operating procedure as recommended by the manufac-
turer is used, a TEG-ROTEM Working Group was
established in 2006. The results shown in this study
were performed by an international group of investi-
gators from several countries, but showed significant
variation between laboratories and instruments.
Although one study from Germany reports a multi-
centre (six centres) investigation of results using the
ROTEM to be consistent, where the CV’s were £14%
for the CT and CFT [12], we were unable to reproduce
this finding. Lang et al. performed the study using
whole blood while we used frozen plasma which may
have contributed to the variability, as the whole blood
assay may be more reproducible compared to the
plasma based assay. There was significant variation
from laboratory to laboratory in our study indicating
that operator variability may play a large role in the
results that were obtained.
Thromboelastography is a promising tool for the
evaluation of hemostasis but cannot be utilized to its
full capacity until studies demonstrate the reliability and
reproducibility of the assay. These results show us that
there remains a great need for continued efforts to
standardize the test, and this has been the first large,
collaborative, international effort in this direction. As a
group with vested interest in this assay we hope to
continue our efforts to standardize the assay and
provide useful information to facilitate the use of this
test in the assessment of coagulation.
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